Clinical Study of Nasopharyngeal Carcinoma Treated by Helical Tomotherapy in China: 5-Year Outcomes

Table 3

Chemotherapy and anti-EGFR monoclonal antibody (Mab) treatment.

Chemotherapy	Concurrent anti-EGFR; Mab treatment		Total
	+	−
None	30	31	61
NACT*	1	5	6
CCT	22	26	48
ACT	21	14	35
NACT + CCT	0	10	10
CCT + ACT	2	24	26
NACT + CCT + ACT	1	0	1
NACT + ACT	3	0	3
Total	80	110	190

∗NACT: neoadjuvant chemotherapy, CCT: concurrent chemotherapy, and ACT: adjuvant chemotherapy.